Search Results

completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

Sampedro-Castaneda, Marisol1, Claxton, Suzanne1, Skehel, Mark2, Ultanir, Sila K.1 1Kinases and Brain Development Mihaylov " I am a postdoctoral researcher in the kinases and brain development laboratory led by Dr Sila moved to King's College London, where my interest and passion for kinases in brain health and disease developed I have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

One example of our recent work surrounds a structure-based effort to develop ligands that specifically Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable

Together with Irina Kufareva , UCSD, her team developed a novel approach to identifying ligands for orphan GPCRs by developing a powerful new computational tool for identifying ‘surrogate’ ligands (borrowed

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed

Mid-career, he has worked in finance and developed high-frequency trading systems. early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development

consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development

His research interest lies in understanding the molecular basis for human tumor development and how to Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor His research aims to translate these novel agents to testing in clinical trials with the hope to develop the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development

Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several permanent member of the Scientific Advisory Board (SAB) of Surface Oncology, a clinical stage company developing

In 2005 he started working on the development of conformational thermostabilization of GPCRs, which resulted In 2016 mini-G proteins were developed as a tool for the structure determination of GPCRs in the fully

insightful experiences in academic, hospital, and industry labs, I decided to pursue a role in business development intersection of science and business, which includes target selection, preclinical strategy and business development to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development

He has focussed on developing a comprehensive map of ovarian cancer essential genes using whole genome Several of these targets are being developed for potential new therapeutic strategies in ovarian and

mispronunciations, cultural differences, and the importance of a multidisciplinary approach in drug development discussed their research interests, particularly in the field of GPCR, and the importance of method development discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach in drug development They also highlighted the importance of method development, integrity, and honesty in scientific research

and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological

He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new

discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic development

We partner with leading experts to develop unique, instructor-created content, ensuring fresh perspectives Develop content : create unique course materials, including slides, reading material, or anything else Terry Kenakin Development of GPCR Ligands and Therapeutic Drugs Up March 20 – April 10 4 weeks x 1 hour Aside from his vast experience in drug development, not to mention his extensive publication record,

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development

He also discovered and championed a novel prostaglandin EP4 drug candidate for development.

His lab focuses on developing and innovating technologies to solve broad questions in pharmacology, with

receptor 110 (ADGRF1, GPR110), an adhesion GPCR recently deorphanized, plays an important role in in the development activation promotes neurogenic differentiation of neural stem cells, neurite growth, and synaptogenesis of developing Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Abstract "All animals develop

They also explored the possibility of developing an ecosystem for the GPCR University. Developing a Research Ecosystem at GPCR University Yamina and Claudia discussed developing an ecosystem

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development

A large component of his work is centered around dysregulated signaling in cancer and the development